VIP and breast cancer

T. W. Moody*, J. Leyton, I. Gozes, L. Lang, W. C. Eckelman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


VIP1 receptors are present in breast cancer cells, VIP elevates the cAMP and stimulates nuclear oncogene expression in MCF-7 cells. VIPhybrid is a VIP receptor antagonist that inhibits breast cancer proliferation. A VIP analog has been developed for imaging breast tumors. Therefore VIP1 receptors may be utilized for the early detection and treatment of breast cancer.

Original languageEnglish
Pages (from-to)290-296
Number of pages7
JournalAnnals of the New York Academy of Sciences
StatePublished - 1998


Dive into the research topics of 'VIP and breast cancer'. Together they form a unique fingerprint.

Cite this